Loading clinical trials...
Loading clinical trials...
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
M.D. Anderson Cancer Center
NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more
NCT07042100 · Advanced Solid Tumors
NCT05687123 · Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, and more
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05856370 · Spinal Deformity, Spinal Degenerative Disorder, and more
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions